Clinical trials: RhA - Rheumatoid Arthritis
Arthritis, Rheumatoid
Repeat Dose Subcutaneous Rhumatoid Arthritis Efficacy Study
This study is a randomised, single-blind, placebo-controlled, repeat dose study of otelixizumab administered subcutaneously in rheumatoid arthritis patients.
- Trial name
- NCT01101555
- Testing
- subcutanious administration
- Where
- Russia
- Volunteers
- 28 people
- Sponsor
- GlaxoSmithKline
Rheumatoid Arthritis (RA)
Methotrexate-Inadequate Response Study
The purpose of this study is to determine whether a weekly subcutaneous dose of abatacept yields clinical efficacy comparable to that of monthly intravenous doses of abatacept in participants with rheumatoid arthritis and an…
- Trial name
- NCT00559585
- Testing
- Subcutaneous (SC) Abatacept, Intravenous (IV) Abatacept
- Where
- 203 sites in United States, Argentina and 22 more
- Volunteers
- 2,492 people
- Sponsor
- Bristol-Myers Squibb
Rheumatoid Arthritis
Study to Evaluate the Safety, Tolerability, and Action of AMG 357 in Females With Rheumatoid Arthritis
The purpose of the study is to find out if AMG 357 is safe and tolerated by women with Rhematoid Arthritis.
- Trial name
- NCT02499315
- Testing
- AMG 357
- Where
- 2 sites in United States
- Volunteers
- 32 people
- Sponsor
- Amgen
Rheumatoid Arthritis (RA)
A Study in Rheumatoid Arthritis Patients Who Have Completed a Preceding Study With ABBV-105 Given Alone or in Combination With Upadacitinib
This was a long-term extension (LTE) study to assess the safety, tolerability, and efficacy of ABBV-105 (elsubrutinib [ELS]) and ABBV-599 (ELS 60 mg and upadacitinib [UPA] 15 mg) in participants with rheumatoid arthritis (RA) who…
- Trial name
- NCT03823378
- Testing
- Elsubrutinib, Upadacitinib
- Where
- 30 sites in Belgium, Canada and 5 more
- Volunteers
- 97 people
- Sponsor
- AbbVie
Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathies
A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis.
The purpose of this study is to measure the safety, tolerability, PK, and PD of AZD5492 administered subcutaneously in adult participants with SLE or IIM or RA Study details include: The study duration will be a minimum of 180…
- Conditions
- Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathies, Rheumatoid Arthritis
- Trial name
- TITAN (NCT06916806)
- Testing
- AZD5492
- Where
- 38 sites in United States, Canada and 8 more
- Volunteers
- 72 people
- Sponsor
- AstraZeneca
Rheumatoid Arthritis
A Study in Rheumatoid Arthritis (RA) Patients to Compare Two Formulations of Adalimumab for Pharmacokinetic, Pharmacodynamic and Safety
A study in Rheumatoid Arthritis (RA) patients to evaluate two formulations of adalimumab for pharmacodynamics, pharmacokinetics, and safety.
- Trial name
- NCT01712178
- Testing
- Adalimumab, current formulation, Adalimumab, new formulation
- Where
- 21 sites in United States, Belgium and 5 more
- Volunteers
- 100 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Rheumatoid Arthritis
A Study of Adalimumab in Adult Japanese Subjects With Rheumatoid Arthritis
The primary objective of this study is to evaluate the safety, efficacy and pharmacokinetics of three doses of adalimumab in adult Japanese subjects with RA
- Trial name
- NCT00647491
- Testing
- adalimumab
- Where
- 25 sites in Japan
- Volunteers
- 352 people
- Sponsor
- Abbott
Rheumatoid Arthritis
Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate
The purpose of this study is to determine the effective dose of BMS-945429 in subjects with inadequate response to Methotrexate in the treatment of moderate to severe Rheumatoid Arthritis.
- Trial name
- NCT01373151
- Testing
- BMS-945429, Methotrexate
- Where
- 100 sites in United States, Argentina and 17 more
- Volunteers
- 418 people
- Sponsor
- CSL Behring
Osteoarthritis, Avascular Necrosis
Post-PMA Approval Study: 10 Year Follow-Up IDE Subjects
primary endpoint of this Study is maintenance of "at least good clinical status" for a period of 10 years following initial implantation among Cormet procedures enrolled inthe pre-market IDE.
- Conditions
- Osteoarthritis, Avascular Necrosis, Rheumatoid Arthritis
- Trial name
- PAS:IDE (NCT00721994)
- Testing
- Cormet Hip Resurfacing System
- Where
- 5 sites in United States
- Volunteers
- 231 people
- Sponsor
- Corin
Rheumatoid Arthritis
Study to Describe Real World Drug Retention Rate of the Tocilizumab at One Year
This multicenter, prospective, non-interventional study is designed to obtain an accurate estimation of the drug retention rate of Tocilizumab (TCZ) Subcutaneously (SC) under real-world conditions in participants with moderate to…
- Trial name
- NCT02608112
- Testing
- Methotrexate, Tocilizumab
- Where
- 77 sites in France
- Volunteers
- 291 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
A Study to Assess the Receptor Occupancy of CD86 and CD80 in Subjects With Rheumatoid Arthritis Initiating Abatacept
The purpose of this study is to characterize CD86 receptor occupancy in subjects with rheumatoid arthritis (RA) receiving abatacept.
- Trial name
- NCT01339481
- Testing
- abatacept
- Where
- 7 sites in United States
- Volunteers
- 26 people
- Sponsor
- Astellas Pharma Inc
Osteoarthritis, Hip, Rheumatoid Arthritis
Avenir Müller Hip Stem Post Market Surveillance Study
This study is a Post Market Clinical Follow up study to fulfil the post market surveillance obligations according to Medical Device Directive and European Medical Device Vigilance System (MEDDEV) 2.12-2.
- Conditions
- Osteoarthritis, Hip, Rheumatoid Arthritis, Fracture of Hip, Dislocated Hip
- Trial name
- NCT04079127
- Testing
- Patients who met the inclusion/exclusion criteria to receive the Avenir Müller stem.
- Volunteers
- 150 people
- Sponsor
- Zimmer Biomet
Osteoarthritis; Rheumatoid Arthritis; Post Traumatic Arthritis
Cup Position in THA With Standard Instruments
Prospective, global, multicenter study to assess cup position in THA. After written informed consent has been obtained, study evaluations will be collected from the pre-op clinic visit, the operative visit (including discharge)…
- Trial name
- NCT03189303
- Testing
- Primary Uncemented Total Hip Arthroplasty
- Where
- 11 sites in United States, Italy and 2 more
- Volunteers
- 183 people
- Sponsor
- DePuy Orthopaedics
Hip Osteoarthritis, Noninflammatory Degenerative Joint Disease
Randomized Controlled RSA Study Comparing the Taperloc Complete Versus the Taperloc Complete Microplasty.
This is a single center, prospective, randomized controlled study. The primary objective of this study is to measure migration over two years with RSA.
- Conditions
- Hip Osteoarthritis, Noninflammatory Degenerative Joint Disease, Avascular Necrosis, Correction of Functional Deformity
- Trial name
- NCT03409666
- Testing
- Taperloc Complete Microplasty stem, Taperloc Complete Reduced Distal stem
- Where
- Netherlands
- Volunteers
- 50 people
- Sponsor
- Zimmer Biomet
Rheumatoid Arthritis
Atacicept in Anti-Tumor Necrosis Factor Alpha-naïve Subjects With Rheumatoid Arthritis (AUGUST II)
The primary objective of this study is to evaluate the efficacy of atacicept compared to placebo in the treatment of signs and symptoms in a subject population with active rheumatoid arthritis (RA), inadequate response to…
- Trial name
- AUGUST II (NCT00595413)
- Testing
- Atacicept: with loading dose, Atacicept, Adalimumab
- Where
- 2 sites in United States, Germany
- Volunteers
- 311 people
- Sponsor
- EMD Serono
Rheumatoid Arthritis
Comparative Pharmacokinetic Trial of RGB-03 and MabThera
Pharmacokinetic properties, efficacy, safety and tolerability of RGB-03 and MabThera will be compared in patients suffering from Rheumatoid Arthritis.
- Trial name
- NCT02371096
- Testing
- MabThera (rituximab), RGB-03
- Sponsor
- Gedeon Richter Plc.
Rheumatoid Arthritis
CF101 Therapy Compared to Methotrexate Therapy for Active Rheumatoid Arthritis
This trial will test the hypothesis that the administration of CF101, a novel anti-inflammatory agent, to patients with rheumatoid arthritis will relieve signs and symptoms of the disease.
- Trial name
- NCT02647762
- Testing
- CF101 1 mg, CF101 2 mg, MTX
- Where
- 35 sites in Bosnia and Herzegovina, Canada and 5 more
- Volunteers
- 244 people
- Sponsor
- Can-Fite BioPharma
Rheumatoid Arthritis
Combination Therapy of F8IL10 and Methotrexate in Rheumatoid Arthritis Patients
Phase I, multicenter, open-label, dose escalation study to test the efficacy and safety of F8IL10 and methotrexate when given as a combination in rheumatoid arthritis patients.
- Trial name
- NCT02076659
- Testing
- F8IL10, Methotrexate
- Where
- 5 sites in Italy
- Volunteers
- 36 people
- Sponsor
- Philogen S.p.A.
Arthritis, Rheumatoid
Long-term Efficacy and Safety of Repeated Ofatumumab Treatment Courses in RA Patients Who Previously Received Ofatumumab or Placebo in Trial Hx-CD20-403
A 3-year open-label trial for patients who previously participated in Trial Hx-CD20-403 and who fulfill the eligibility criteria for this trial (GEN413) .
- Trial name
- NCT00655824
- Testing
- ofatumumab
- Where
- 10 sites in United States, Denmark and 3 more
- Volunteers
- 124 people
- Sponsor
- GlaxoSmithKline
Rheumatoid Arthritis
A Study of the Safety, Pharmacokinetics, and Pharmacodynamics of MTRX1011A in Patients With Rheumatoid Arthritis
This is a Phase I multicenter study that will be conducted in the United States and consists of a double-blind, placebo-controlled, SAD stage, followed by a double-blind, placebo controlled MAD stage.
- Trial name
- NCT00718588
- Testing
- MTRX1011A
- Volunteers
- 66 people
- Sponsor
- Genentech, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.